 
Exalenz Bioscience Ltd.      CONFIDENTIAL AND PROPRIETARY   
 
 
Companion protocol for the ¹³C -Methacetin Breath Test  
(MBT)  for use in Bristol -Myers Squibb  phase  2b studies 
for BMS -986036  (PEG -FGF21 ), under Protocol s 
MB130 -068 and MB130 -069  
  
Protocol No. BMS -EX-0118  
 
Document N o: CSP000002  Total pages: 38 
Version Level: 1.0 Last update on:  February  20, 2018 
 
 Name  Position  
Author / 
Owner  Ora Msika -Azuelos  Clinical Regulatory Affairs Manager  
Reviewed by  Gil Guggenheim  Clinical Research Development Manager  
Approved by  Ofer Schlesinger  VP R&D  
Electronic signatures and approvals, effective information and Lifecycle Status can be 
obtained by accessing the system generated approval page associated with this document.  
The system generated approval page can be retrieved from the PDM system.  
This publication, in whole or in part, may not be reproduced, disclosed, translated into 
any language or computer language or distributed without the prior written consent of:  
Exalenz Bioscience  Ltd. 4 Ha’Maayan St. Modi ’in, Israel 7177872  
Versions  Control:  
Version  Date  Responsible Person  Description of Change  
1.0 February  20, 2018 Ora Msika -Azuelos  Initial Release  
    

Exalenz Bioscience Ltd.  Last update : February 20, 2018  
Study Title: Companion protocol for the ¹³C -Methacetin Breath 
Test (MBT)  for use in  Bristol -Myers Squibb phase  2b studies 
for BMS -986036  (PEG -FGF21) , under Protocols MB130 -068 
and MB130 -069 Protocol: BMS -EX-0118  
Version:  1.0 
Document No:  CSP000002  Page 2 of 38 
 
Exalenz Bioscience Ltd.    201 8  CONFIDENTIAL AND PROPRIETARY  1 ABBREVIATIONS  
AE - Adverse Event  
BMS  -  Bristol -Myers Squibb  
CDOB  - Cumulative  Delta over Baseline  
CI - Confidence Interval  
CL - Confidence Limits  
CO 2 - Carbon dioxide  
CPDRxx  - Cumulative Percentage Dose Recovery at xx minutes from ingestion  
CRF  - Case Report Form  
CSPH  -  Clinically Significant Port Hypertension  
CTP - Child -Turcotte -Pugh Score  
DOB  - Delta over Baseline  
eCRF  - Electronic Case Report Form  
FDA  - (United States) Food and Drug Administration  
GCP  - Good Clinical Practice  
IDE - Investigational Device Exemption  
IRT - Interactive Response Technology  
MBT  - 13C-Methacetin Breath Test  
MCS  - Molecular Correlation Spectrometry  
MEGX  - Monoethylglycinexylidide  
MELD  - Model for End -Stage Liver Disease  
MRI  - Magnetic Resonance Imaging  
MRE  - Magnetic Resonance Elastography  
NAFLD  - Nonalcoholic Fatty Liver Disease  
NAS  - NAFLD Activity Score  
NASH  - Nonalcoholic Steatohepatitis  
NPV  - Negative Predictive Value  
PDFF  - Proton Density Fat Fraction  
PDR  - Percent Dose Recovered (expressed as % per hour)  
PET - Thermoplastic Polyester  
PO - Per Os (by mouth)  
PTFU  - Post treatment follow up  
QW - Once weekly  
SAE  - Serious Adverse Event  
SF - Screen Failures  
SUSAR  - Suspected unexpected serious adverse reaction  
UADE  - Unanticipated Adverse Device Effect  
Exalenz Bioscience Ltd.  Last update : February 20, 2018  
Study Title: Companion protocol for the ¹³C -Methacetin Breath 
Test (MBT)  for use in  Bristol -Myers Squibb phase  2b studies 
for BMS -986036  (PEG -FGF21) , under Protocols MB130 -068 
and MB130 -069 Protocol: BMS -EX-0118  
Version:  1.0 
Document No:  CSP000002  Page 3 of 38 
 
Exalenz Bioscience Ltd.    201 8  CONFIDENTIAL AND PROPRIETARY  US - United States (of America)  
USA  - United States of America  
  
Exalenz Bioscience Ltd.  Last update : February 20, 2018  
Study Title: Companion protocol for the ¹³C -Methacetin Breath 
Test (MBT)  for use in  Bristol -Myers Squibb phase  2b studies 
for BMS -986036  (PEG -FGF21) , under Protocols MB130 -068 
and MB130 -069 Protocol: BMS -EX-0118  
Version:  1.0 
Document No:  CSP000002  Page 4 of 38 
 
Exalenz Bioscience Ltd.    201 8  CONFIDENTIAL AND PROPRIETARY    
TABLE OF CONTENTS  
1 Abbreviations  ................................ ................................ ................................ ........................  2 
2 Protocol Synopsis  ................................ ................................ ................................ .................  7 
3 Background  ................................ ................................ ................................ .........................  14 
3.1 Defining the need for a non -invasive test for the characterization of NASH progression  ...........  15 
3.2 Rationale to use the MBT for assessment of Liver Disease Progression  ................................ ..... 16 
4 Intended Use / Indication for Use  ................................ ................................ .....................  17 
5 Study Design  ................................ ................................ ................................ .......................  17 
6 Subject Sele ction  ................................ ................................ ................................ .................  18 
6.1 Inclusion Criteria  ................................ ................................ ................................ ..........................  18 
6.2 Exclusion Criteria ................................ ................................ ................................ .........................  18 
6.3 Exclusion Criteria from MBT testing On the day of the test  ................................ .......................  19 
6.4 Consenting  ................................ ................................ ................................ ................................ ... 19 
7 Study Objectives  ................................ ................................ ................................ .................  20 
7.1 Primary Efficacy Objective  ................................ ................................ ................................ ..........  20 
7.2 Secondary Efficacy Objectives  ................................ ................................ ................................ .... 20 
7.3 Exploratory Efficacy Objectives  ................................ ................................ ................................ .. 21 
7.4 MBT Safety Objective  ................................ ................................ ................................ .................  21 
7.5 Primary Efficacy Endpoint  ................................ ................................ ................................ ...........  21 
7.6 Secondary Efficacy Endpoint measures  ................................ ................................ .......................  21 
7.7 Efficacy Variables  ................................ ................................ ................................ ........................  22 
7.7.1  Liver Biopsy  ................................ ................................ ................................ ................................ .. 23 
7.7.2  Clinical Outcome Events  ................................ ................................ ................................ ...............  24 
Exalenz Bioscience Ltd.  Last update : February 20, 2018  
Study Title: Companion protocol for the ¹³C -Methacetin Breath 
Test (MBT)  for use in  Bristol -Myers Squibb phase  2b studies 
for BMS -986036  (PEG -FGF21) , under Protocols MB130 -068 
and MB130 -069 Protocol: BMS -EX-0118  
Version:  1.0 
Document No:  CSP000002  Page 5 of 38 
 
Exalenz Bioscience Ltd.    201 8  CONFIDENTIAL AND PROPRIETARY  7.7.3  Magnetic Resonance Elastography (MRE)  ................................ ................................ ....................  24 
7.7.4  Fibroscan® Elastography  ................................ ................................ ................................ ...............  25 
7.7.5  Magnetic Resonance Imaging (MRI)  ................................ ................................ ............................  25 
7.7.6  Serum Biomarker Pro -C3 ................................ ................................ ................................ ..............  26 
7.7.7  MELD Scoring  ................................ ................................ ................................ ..............................  26 
7.7.8  Child-Turcotte -Pugh (CTP) Scoring  ................................ ................................ ..............................  27 
7.7.9  13C-Methacetin Breath Test (MBT)  ................................ ................................ ...............................  27 
8 Safety Termination and Early Withdrawal of Subjects or Study  ................................ . 28 
8.1 Expected Study Duration  ................................ ................................ ................................ .............  28 
9 Statistical Considerations  ................................ ................................ ................................ .. 28 
9.1 Study Design and Aim  ................................ ................................ ................................ .................  28 
9.2 Endpoint Measures  ................................ ................................ ................................ .......................  28 
9.2.1  Primary endpoint measure  ................................ ................................ ................................ .............  28 
9.2.2  Secondary endpoint measures  ................................ ................................ ................................ ........  29 
9.2.3  Safety endpoints measure  ................................ ................................ ................................ ..............  30 
9.3 Acceptance Criteria (Study Hypotheses)  ................................ ................................ .....................  30 
9.4 Sample Size  ................................ ................................ ................................ ................................ .. 30 
9.5 Analysis sets  ................................ ................................ ................................ ................................ . 31 
9.6 Statistical Analysis  ................................ ................................ ................................ .......................  31 
9.6.1  General Considerations  ................................ ................................ ................................ ..................  31 
9.6.2  Demographic and other Baseline Characteristics  ................................ ................................ ..........  32 
9.6.3  Disposition of Subjects  ................................ ................................ ................................ ..................  32 
9.6.4  Safety Analysis  ................................ ................................ ................................ ..............................  32 
9.6.5  Interim Anal ysis ................................ ................................ ................................ ............................  32 
9.6.6  Pooling  ................................ ................................ ................................ ................................ ...........  33 
Exalenz Bioscience Ltd.  Last update : February 20, 2018  
Study Title: Companion protocol for the ¹³C -Methacetin Breath 
Test (MBT)  for use in  Bristol -Myers Squibb phase  2b studies 
for BMS -986036  (PEG -FGF21) , under Protocols MB130 -068 
and MB130 -069 Protocol: BMS -EX-0118  
Version:  1.0 
Document No:  CSP000002  Page 6 of 38 
 
Exalenz Bioscience Ltd.    201 8  CONFIDENTIAL AND PROPRIETARY  9.6.7  Handling of Missing Data  ................................ ................................ ................................ ..............  33 
10 Study Procedures  ................................ ................................ ................................ ...............  33 
10.1  General  ................................ ................................ ................................ ................................ .........  33 
10.2  Breath Test  Procedure  ................................ ................................ ................................ ..................  33 
10.3  Investigational Product Handling  ................................ ................................ ................................ . 35 
10.4  Investigational Product Accountability  ................................ ................................ ........................  36 
11 Ethics & Regulatory Considerations  ................................ ................................ ................  36 
12 Safety Considerations  ................................ ................................ ................................ ........  36 
13 Subject Confidentiality  ................................ ................................ ................................ ...... 37 
14 Monitoring and Quality Assurance  ................................ ................................ ..................  37 
15 Publication Policy and Finance  ................................ ................................ .........................  37 
16 Financial Aspects  ................................ ................................ ................................ ................  37 
17 Study termination  ................................ ................................ ................................ ...............  37 
18 References  ................................ ................................ ................................ ...........................  37 
  
Exalenz Bioscience Ltd.  Last update : February 20, 2018  
Study Title: Companion protocol for the ¹³C -Methacetin Breath 
Test (MBT)  for use in  Bristol -Myers Squibb phase  2b studies 
for BMS -986036  (PEG -FGF21) , under Protocols MB130 -068 
and MB130 -069 Protocol: BMS -EX-0118  
Version:  1.0 
Document No:  CSP000002  Page 7 of 38 
 
Exalenz Bioscience Ltd.    201 8  CONFIDENTIAL AND PROPRIETARY  2 PROTOCOL SYNOPSIS  
Protocol Title:  Companion protocol for the ¹³C -Methacetin Breath Test for use in  Bristol -
Myers Squibb  phase  2b studies for BMS -986036  (PEG -FGF21 ), under 
Protocol s MB130 -068 and MB130 -069. 
Short Title:  Companion protocol assessing the MBT in  subjects participating in the 
MB130 -068 and MB130 -069-studies (PEG -FGF21 ) 
Protocol Number:  BMS -EX-0118  
Version and Date:  v 1.0,  February 20, 2018  
Phase of 
Development  of 
BMS -986036 : Phase 2b (IND 125297 ) 
Phase of 
Development of 
MBT:  The study is feasibility for drug response monitoring however the data may 
be used for Exalenz for future submissions  
Sponsor:  Exalenz Bioscience Ltd.  
4 Ha ’Maayan Street  
Modi'in, Israel 71778 72 
Tel: +972 -8-9737500  
Fax: +972 -8-9737501  
Investigated 
Disease:  Subjects with Non -Alcoholic S teatohepatitis (NASH)  and stage 3 liver 
fibrosis (MB130 -068 study) or compensated  liver cirrhosis  (MB130 -069 
study)  
Combination 
Product:  ¹³C-labeled  Methacetin Breath Test  
Comparators:  Liver Fibrosis stage  as assessed by  biopsy and additional liver health 
measures  and their changes  such as  NAS , MELD , CTP, PDFF,  Liver 
Stiffness , Serum Biomarker Pro -C3, and Liver -related  Clinical Outcome . 
Exalenz Bioscience Ltd.  Last update : February 20, 2018  
Study Title: Companion protocol for the ¹³C -Methacetin Breath 
Test (MBT)  for use in  Bristol -Myers Squibb phase  2b studies 
for BMS -986036  (PEG -FGF21) , under Protocols MB130 -068 
and MB130 -069 Protocol: BMS -EX-0118  
Version:  1.0 
Document No:  CSP000002  Page 8 of 38 
 
Exalenz Bioscience Ltd.    201 8  CONFIDENTIAL AND PROPRIETARY  Study Population:  Subjects  that are  enrolled into either of two separate BMS sponsored IND 
studies (MB130 -068, MB130 -069) at selected study sites  will be offered  the 
opportunity  to perform the MBT . These will be considered as two separate 
study cohorts (cohort 1  and 2, respectively)  within this companion protocol.  
Each cohort consists of four treatment arms (BMS -986036 10mg, 20mg, 
40mg QW or matching placebo QW) , as defined in the respective BMS 
sponsored protocols.  
 
Cohort 1 consists of Subjects  with NASH and stage 3 fibrosis , as assessed 
by a central laboratory reader of the liver biops ies (n=160 ), and who  meet all 
the MB130 -068 study criteria . 
 
Cohort 2  consists of Subjects  with NASH and compensated  liver cirrhosis  
(stage 4 fibrosis) , as assessed by a central laboratory reader of the liver 
biops ies (n=100 ), and who  meet all the MB130 -069 study criteria.  
 
This feasibility companion protocol will include the 2 cohorts of subjects , 
with a planned total of up to 260 subjects from approximately 75 sites 
worldwide (USA  and Japan ) for the two BMS IND studies, while the MBT 
will only be conducted in the USA .  
Not all participating sites will elect to perform the MBT. The total number 
of subjects expected to perform the MBT may reach up to 250 subjects  (also 
accounting for drop outs) . Each subject will perform up to 3 MBTs over 1 
year; approximately on e every 24 weeks . 
Primary Efficacy 
Objectives:  To demonstrate the ability of the MBT to evaluate patient response to 
treatment with BMS -986036 , comparing placebo to each treatment arm  
individually . Assessment will be performed at the 24 and 48 week visits and 
compared to  day 1 (change from baseline) and the respective preceding visit  
(change between visits) , when available . Assessments will be done for each 
study cohort independently , according to availability , and on the combined 
population of the two  cohorts  by dose of the BMS drug under study . 
Exalenz Bioscience Ltd.  Last update : February 20, 2018  
Study Title: Companion protocol for the ¹³C -Methacetin Breath 
Test (MBT)  for use in  Bristol -Myers Squibb phase  2b studies 
for BMS -986036  (PEG -FGF21) , under Protocols MB130 -068 
and MB130 -069 Protocol: BMS -EX-0118  
Version:  1.0 
Document No:  CSP000002  Page 9 of 38 
 
Exalenz Bioscience Ltd.    201 8  CONFIDENTIAL AND PROPRIETARY  Secondary 
Efficacy 
Objectives:  The following a ssessments will be done by treatment arm and combined 
arms for each study cohort independently , according to availability , and on 
the combined population of the two  study cohorts  by dose of the BMS drug 
under study :  
1. To demonstrate the short and long -term prognostic value (3 
months , 6 months and 1 year, respectively) of MBT for liver 
disease deterioration  (reported as liver -related clinical outcome 
events) . Assessment will be performed using MBT from the day 1, 
and 24 and 48 week visits.  
2. To assess the ability of changes in the MBT to  reflect  biopsy 
proven changes in fibrosis and/or NAS  as assessed by a central 
reader  at week 24 (or at least week 20 in case s of an  early 
termination time point) ( for cohort 1 ) or at week 48 ( for cohort 2 ) 
compared to the baseline biopsy from the screening visit.  
3. To assess the ability of changes in the MBT to  reflect  changes in 
liver stiffness as measured by Magnetic Resonance El astography 
(MRE) where available at weeks 24 and 48 (or at early termination)  
compared to baseline MRE from the screening visit . 
4. To assess the ability of changes in the MBT to  reflect  changes in 
Proton Density Fat Fraction (PDFF) as measured by Magnetic 
Resonance Imaging (MRI)  where available - at weeks 24  and 48 (or 
early termination), compared to baseline  MRI from the screening 
visit.  
 
To assess the ability of changes in the MBT to reflect changes in Serum Pro -
C3 at 24 and 48 week s of treatment  (or earl y termination), compared to 
baseline Pro -C3 from the screening visit.  
The following additional objectives are applicable for cohort 2 only:  
1. To assess the ability of changes in the MBT to  reflect  changes in 
liver stiffness as measured by “Fibroscan ” elastog raphy at the 48 
week visit (or earlier if there was an early termination)  compared to 
the screening visit .  
2. To assess the ability of changes in the MBT to reflect changes in 
the Model for End -stage Liver Disease (MELD) score at 24 and 48 
week visits  compared to study day 1 . 
3. To assess the ability of changes in the MBT to  reflect  changes in 
the Child -Turcotte -Pugh Scoring (CTP) score at weeks 24 and 48 
(or early termination)  compared to study day 1 . 
Exalenz Bioscience Ltd.  Last update : February 20, 2018  
Study Title: Companion protocol for the ¹³C -Methacetin Breath 
Test (MBT)  for use in  Bristol -Myers Squibb phase  2b studies 
for BMS -986036  (PEG -FGF21) , under Protocols MB130 -068 
and MB130 -069 Protocol: BMS -EX-0118  
Version:  1.0 
Document No:  CSP000002  Page 10 of 38 
 
Exalenz Bioscience Ltd.    201 8  CONFIDENTIAL AND PROPRIETARY  Exploratory 
Efficacy 
Objectives:  To assess the abili ty of the MBT to monitor patient status in comparison to 
other available measures, such as Liver Fibrosis stage , NAS, MELD, CTP , 
PDFF, Liver Stiffness, Serum Biomarker or Pro -C3.  
Safety Objective:  Evaluation of safety related to the MBT . 
Exalenz Bioscience Ltd.  Last update : February 20, 2018  
Study Title: Companion protocol for the ¹³C -Methacetin Breath 
Test (MBT)  for use in  Bristol -Myers Squibb phase  2b studies 
for BMS -986036  (PEG -FGF21) , under Protocols MB130 -068 
and MB130 -069 Protocol: BMS -EX-0118  
Version:  1.0 
Document No:  CSP000002  Page 11 of 38 
 
Exalenz Bioscience Ltd.    201 8  CONFIDENTIAL AND PROPRIETARY  Study Design:  This study is a feasibility companion protocol that will  rely on the data 
generated by BMS' s studies of BMS -986036  (PEG -FGF21 ) under protocols 
MB130 -068 and MB130 -069 (IND  125297) , which are assessed in this 
companion protocol as two separate study cohorts  (1 and 2, respectively)  
with the exception of the MBT . The MB130 -068 and MB130 -069 studies 
are Phase 2b, multicenter, double -blind, randomized, placebo -controlled, 
parallel -group studies to demonstrate the safety and efficacy of BMS -
986036 in the treatmen t of subjects with NASH and stage 3 liver fibrosis or 
compensated cirrhosis with up to 48 weeks of treatment.  The study is 
feasibility for drug response monitoring however the data may be 
used for Exalenz for future submissions . 
 
As de scrib ed in the BMS protocols, subjects will be enrolled and 
randomized via intera ctive response technology (IRT)  to receive BMS -
9860936 10mg QW, BMS -986036 20mg QW, BMS -9860936 40mg QW or 
matching placebo QW in a 1:1:1:1 ratio.  
 
The BMS studies' treatment durations will each  consist of two periods:  
1. A 48 -week, Double -Blind Treatment Period, during which the 
subjects will receive blinded study medication (BMS -986036 
10mg, 20 mg, 40mg QW or matching placebo QW). During the 
Double -Blind Treatment Period, subjects will be evaluated for 
safety and efficacy  every 4 weeks (±5 days) through week 24 and 
every 8 weeks (±5 days) from week 24 through week 48.  
2. A Follow up Period, during which subjects will be evaluated for 
safety and efficacy for 4 weeks through week 52. 
3. A Follow -Up Period of at least 6 months and up to 14 months after 
the week 52/  PTFU Visit for the collection of additional DXA 
assessment (in all participants) and immunogenicity assessments 
(in participants for whom Long -Term Immunogenicity Follow -Up 
Visits are required.)  Any liver related complica tion event will be 
recorded.  
 
The last dose of study medication will be at the week 48 visit. Subjects will 
have a safety and efficacy evaluation at week 48 and return for a post -
treatment follow -up evaluation through week 52.  
 
As a sub -study of BMS proto cols MB130 -068 and MB130 -069, MBT will 
be performed at the day 1 visit and every 24 weeks during the Double -Blind 
Treatment Period in order to allow the assessment whether BMS -986036 
compared to placebo improves liver metabolic function as determined by th e 
MBT.  
Exalenz Bioscience Ltd.  Last update : February 20, 2018  
Study Title: Companion protocol for the ¹³C -Methacetin Breath 
Test (MBT)  for use in  Bristol -Myers Squibb phase  2b studies 
for BMS -986036  (PEG -FGF21) , under Protocols MB130 -068 
and MB130 -069 Protocol: BMS -EX-0118  
Version:  1.0 
Document No:  CSP000002  Page 12 of 38 
 
Exalenz Bioscience Ltd.    201 8  CONFIDENTIAL AND PROPRIETARY  Inclusion Criteria:  This protocol follows the inclusion criteria as defined in the respective main 
protocols; MB130 -068 and MB130 -069 are considered as two distinct study 
cohorts for this companion protocol . This  feasibility  companion protocol 
intends to assess the data for all subjects that perform the MBT  under the 
MB130 -068 and MB130 -069 protocols, including their clinical follow up 
information . 
Exclusion 
Criteria:  Exclusion criteria are defined in the respective main protocols;  MB130 -068 
and MB130 -069, and are  considered as two distinct study cohorts for this 
feasibility companion protocol . Additionally, subjects designated to perform 
the MBT that are known to be hypersensitive or allergic to Methacetin or its 
metabolites, e.g. acetaminophen  (paracetamol), will not perform the MBT.  
Pre Breath Test 
Restrictions:  1. Subject should be fasting, including all oral morning medications 
(except for beta -blockers and study drug [BMS -986036 or placebo]), for 
at least 8 hours prior to the test  
2. Subject sh ould not smoke on the day of the breath test prior to the breath 
test  
3. Subject should not take any of the following drugs within 48 hours prior 
to the test: acyclovir, allopurinol, carbamazepine, cimetidine, 
ciprofloxacin, daidzein (herbal), disulfiram, ec hinacea, enoxacin, 
famotidine, fluvoxamine, methoxsalen, mexiletine, montelukast, 
norfloxacin, phenylpropanolamine, phenytoin, propafenone, rifampin, 
terbinafine, ticlopidine, thiabendazole, verapamil, zileuton or any 
medication that might interfere with m ethacetin metabolism or might 
affect CYP1A2 (cytochrome P450 1A2)  
4. Subject should not take amiodarone within 30 days prior to the test  
5. Subject should not take paracetamol (acetaminophen) related 
medications within the 24 hours prior to the test  
6. Subject sh ould not perform the test if allergic or hypersensitive to 
Methacetin or its metabolites (paracetamol, acetaminophen)  
7. Subject should not consume any alcohol or caffeine within 24 hours 
prior to the test  
8. Subject should not have general anesthesia or sedation within 24 hours 
prior to the test  
9. Subjects on beta -blockers or statins should be on a stable dose at least 30 
days prior to the test  
Exalenz Bioscience Ltd.  Last update : February 20, 2018  
Study Title: Companion protocol for the ¹³C -Methacetin Breath 
Test (MBT)  for use in  Bristol -Myers Squibb phase  2b studies 
for BMS -986036  (PEG -FGF21) , under Protocols MB130 -068 
and MB130 -069 Protocol: BMS -EX-0118  
Version:  1.0 
Document No:  CSP000002  Page 13 of 38 
 
Exalenz Bioscience Ltd.    201 8  CONFIDENTIAL AND PROPRIETARY  Primary Efficacy 
Endpoint  The MBT's ability to measure the effect of BMS -986036 treatment on the 
metabolic capacity of the liver at  24-week intervals during the Double -Blind 
Treatment Period , as compared to changes in placebo treated subjects.  
Secondary 
Efficacy Endpoint 
measures:  In order to assess the correlation of MBT with other measures of liver 
disease, the following endpoint measures will be collected:  
For all study cohorts: MBT results for each MBT visit (day 1 , week 24, 
week 48 ) as well as changes in MBT results (CPDR30/PDR peak or other 
breath test parameters).  
 
The other measures of liver disease that will also be collected in this study 
are as follows:  
 
Liver Fibrosis stage and NAS as determined by Liver Biopsy, PDFF as 
determined by MRI  where available , Liver Stiffness as determined by MRE 
where available , Serum Biomarker Pro -C3.  
 
Additional mea sures for cohort 2 include: MELD and CTP scores , Liver 
Stiffness as determined by Fibroscan® Elastography, Liver -related  Clinical 
Outcome  defined as the first occurrence of any one of the following: all -
cause mortality, MELD score ≥15, liver transplant, he patocellular carcinoma 
(HCC), ascites requiring medical intervention, hospitalization (≥ 24 hours) 
for onset of variceal bleeding, hepatic encephalopathy and spontaneous 
bacterial peritonitis.  
Statistical 
Analysis:  The 13C-Methacetin Breath Test will primarily be assessed for its ability to 
measure the effect of BMS -986036 on the metabolic capacity of the liver at 
24-week intervals during the Double -Blind Treatment Period as compared to 
placebo, by modelling the MBT results and the change in its value from 
previous visits, including the baseline MBT, to each of the subsequent visits  
using Mixed Effect Model for Repeat Measurements (MMRM).  
Secondary endpoints will be assessed through Cox and Linear regressions in 
order to test for prognostic value and co rrelations between MBT and other 
Liver related outcomes and measures.  
Exalenz Bioscience Ltd.  Last update : February 20, 2018  
Study Title: Companion protocol for the ¹³C -Methacetin Breath 
Test (MBT)  for use in  Bristol -Myers Squibb phase  2b studies 
for BMS -986036  (PEG -FGF21) , under Protocols MB130 -068 
and MB130 -069 Protocol: BMS -EX-0118  
Version:  1.0 
Document No:  CSP000002  Page 14 of 38 
 
Exalenz Bioscience Ltd.    201 8  CONFIDENTIAL AND PROPRIETARY  3 BACKGROUND  
Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic 
liver disease in the world today. Nonalcoholic steatohepatitis (NASH), which is the most  
progressive form of NAFLD, is defined as the presence of hepatic steatosis and 
inflammation with hepatocyte injury (ballooning), with or without fibrosis. NASH is 
associated with increased mortality rates due to cardiovascular -, liver -, and cancer -related  
deaths.   
Currently, there are no approved drugs for the treatment of NASH. With the increasing 
prevalence of obesity and obesity -related diseases, NASH could soon become the leading  
indication for liver transplantation and the leading cause of hepatocellu lar carcinoma 
(HCC). There is an urgent need to develop preventative and therapeutic strategies against 
NASH , as clearly described in the BMS' -studies main protocol s. 
Standard biochemical and clinical tests are not capable of providing good correlation s with 
disease staging and grading. Furthermore, it is known that in a substantial percentage of the 
diseased population, standard liver function tests do not show abnormal results . 
Histolog ical parameters have  been  shown to be correlated to liver  disease severity ,(1) but 
biopsies have limitations such as sampling error and the risks involved in the biopsy 
procedure  itself . Furthermore, biopsies are not a measure that can be repeated often enough 
in standard practice in order to monitor disease progression  and effect of  therapeutic 
treatments.  
The unmet clinical need for a non -invasive means to evaluate liver disease progression or 
response to therapy accurately is clearly a challenge that needs to be addressed as new 
NASH treatments are being developed.  
The concept of a  metabolic test that could be utilized to assess the severity of liver disease 
was first explored several decades ago. Such tests are performed by administering a 
compound , either orally or intravenously, with the compound being taken up by the liver or  
metabolized . The end -products of the metabolic process can be measured in either blood, 
bile, urine, saliva or exhaled breath, supplying a measurable value to the level of liver 
metabolic activity . Several compounds have been utilized to evaluate hepatic met abolic 
function in this manner, including indocyanine green, galactose, aminopyrine, caffeine, 
lidocaine, phenylalanine, Methacetin (N -(4-Methoxy -phenyl) acetamide) and Octanoate 
(sodium -octanoate). For example, previous studies have demonstrated that hepa tic 
metabolism of lidocaine to monoethylglycinexylidide (MEGX) decreases with liver 
fibrosis and cirrhosis and improves with successful treatment of the underlying liver 
disease. Furthermore, these studies showed the lidocaine test could  accurately predict  
Exalenz Bioscience Ltd.  Last update : February 20, 2018  
Study Title: Companion protocol for the ¹³C -Methacetin Breath 
Test (MBT)  for use in  Bristol -Myers Squibb phase  2b studies 
for BMS -986036  (PEG -FGF21) , under Protocols MB130 -068 
and MB130 -069 Protocol: BMS -EX-0118  
Version:  1.0 
Document No:  CSP000002  Page 15 of 38 
 
Exalenz Bioscience Ltd.    201 8  CONFIDENTIAL AND PROPRIETARY  which subjects  with stable cirrhosis awaiting liver transplantation were at risk of 
develop ing future hepatic decompensation. Most of these methods have been abandoned 
due to impracticality or undesired side effects.  
Exalenz Bioscience Ltd. has developed breath test products consisting of a combination of 
a medical device and various 13C-labeled substrates for gastroint estinal and liver 
applications.  
The rate and pattern of changes in the 13CO 2/12CO 2 ratio curve in exh aled breath  reflect 
substrate metabolism, i.e. the liver's  metabolic capacity.  
The aim of the Company is to provide a non -invasive, point -of-care, breath test to assess 
disease severity and to monitor disease progression  (improvement  or deterioration)  using 
13C-Methacetin.  
3.1 Defining the need for a non -invasive test for the characterization of 
NASH progression  
About 7.9% of the US population has persistently elevated liver enzymes with negative 
findings for viral hepatitis and other common causes of liver diseases(2). Over 80% of such 
cases are estimated to be due to NAFLD (NAFL or NASH). In those who have 
concomitant features of the metabolic syndrome, the likelihood of developing NAFLD 
exceeds 90%. It is also known that in a substantial percentage of the diseased population, 
standard t ests do not show abnormal results, especially in the NAFLD population.  
Furthermore, the standard biochemical and clinical tests do not provide good correlation 
with disease staging and grading.  
Currently, such subjects  are offered a liver biopsy as standard of care to diagnose NASH 
and assess the risk of potential cirrhosis. Although histology results have been shown to be 
correlated to liver disease severity ,(1), biopsies have limitations such as sampling error and 
risks involved in the actual biopsy procedur e. Additionally, given the sheer numbers of 
subjects with NASH in the world, it is not logistically feasible to biopsy all subjects with 
NASH. Furthermore, biopsies are not a measure that can be repeated often enough in 
standard practice in order to monito r disease progression  or response to treatment . 
Based on all of the above, there is a great need for a simple non -invasive method to assess 
and monitor disease progression in the NAFLD/NASH population . 
Breath testing with 13C-labeled substrates provides a safe, non -invasive means for 
evaluating hepatic impairment as it pertains to liver metabolic function. 13C is a stable, non -
radioactive isotope, which can be incorporated into a specific location within a test 
substrate so it can be metabolized to 13CO 2 by the liver. 13C-Methacetin  has been identified 
as such an appropriate substrate.  
The device being used is a molecular correlation based spectrometer, using a patented 
technology based on specific light source emissions and the different absorption of 13CO 2 
Exalenz Bioscience Ltd.  Last update : February 20, 2018  
Study Title: Companion protocol for the ¹³C -Methacetin Breath 
Test (MBT)  for use in  Bristol -Myers Squibb phase  2b studies 
for BMS -986036  (PEG -FGF21) , under Protocols MB130 -068 
and MB130 -069 Protocol: BMS -EX-0118  
Version:  1.0 
Document No:  CSP000002  Page 16 of 38 
 
Exalenz Bioscience Ltd.    201 8  CONFIDENTIAL AND PROPRIETARY  and 12CO 2 gases. This technology is already implemented in a similar device approved for 
marketing in Europe and cleared in the USA for other disease testing, namely  H. pylori  
infection.  
The 13C-labeled substrates (in this case 13C-Metha cetin) are meta bolized by the target organ 
under investigation (in this case the liver), producing 13CO 2 which in turn leads to changes 
in the 13CO 2/12CO 2 ratio in a subject 's exhaled breath over time. These ratio changes are 
displayed in real time on the device's screen and printed at the  end of  the test. 
Breath tests using the 13C-Methacetin are being evaluated in this protocol in an attempt to 
find an effective non-invasiv e tool to monitor liver disease progression/regression with and 
without treatment in NAFLD/NASH, and to assist in assessing disease severity  and risk for 
decompensation . 
3.2 Rationale to  use the MBT for assessment of Liver Disease 
Progression  
Tests of true hep atic function that rely on the metabolism of administered exogenous 
compounds have not yet been widely adopted in clinical practice because they have been 
cumbersome to perform and the acquisition of results is slow . The recent development of 
the BreathID® MCS  analyzer offers a unique opportunity to demonstrate a metabolism -
based test showing agreement with disease progression /regression  and liver biopsy  
measures.  
In advanced liver disorders, the liver has reduced Methacetin metabolic capacity , leading to 
low MBT values. Low values of Methacetin metabolism are suggestive of Subjects  who 
have advanced liver disease. Several MBT output variables (percentage dose recovery rate 
and cumulative percentage dose recovered - PDR/CPDR values at different time points  and 
their combination ) may be used to assess  metabolic capacity and subsequently liver  disease 
progression /regression . 
It has been shown in preliminary studies that MBT  correlate s with both CTP and MELD 
values. It may be even more sensitive and a better predictor of liver function because 
generally function deteriorates prior to the development of complications of cirrhosis and a 
decline in liver function as assessed by CTP and MELD(3).  
It is hypothesized that a decline in liver function as assessed by MBT  measured serially 
over time will occur prior to the development of complications of cirrhosis ( such as 
variceal bl eeding, ascites and hepatic encephalopathy) and worsening in liver function as 
assessed by changes in CTP and MELD . 
The MBT , by providing immediate results , could aid in decision making in Subjects  with 
cirrhosis awaiting liver transplant. Such a test may in the future help in  decision -making 
Exalenz Bioscience Ltd.  Last update : February 20, 2018  
Study Title: Companion protocol for the ¹³C -Methacetin Breath 
Test (MBT)  for use in  Bristol -Myers Squibb phase  2b studies 
for BMS -986036  (PEG -FGF21) , under Protocols MB130 -068 
and MB130 -069 Protocol: BMS -EX-0118  
Version:  1.0 
Document No:  CSP000002  Page 17 of 38 
 
Exalenz Bioscience Ltd.    201 8  CONFIDENTIAL AND PROPRIETARY  regarding transplantation priority and provide point of care assessment of therapeutic 
interventions if relevant.  
All l iver-related clinical outcome events will be captured in this study (see section 7.7.2 ). 
One of t his study’s aim s is to show the ability of the 13C-methacetin breath test  to identify 
Subjects  at risk for decompensation and to determine the effe ct of BMS’  study drug  BMS -
986036  on the metabolic capacity of the liver at 24-week intervals during the Double -Blind 
Treatment Period  compared to placebo . 
4 INTENDED USE / INDIC ATION FOR USE  
The ¹³C -Methacetin Breath Test is a non-invasive test intended as an aid to assess liver 
disease progression  (improvement or deterioration)  with or  without treatment in adult 
subjects  by measuring the ability of the liver to metabolize ¹³C -Methacetin .   The ¹³C-
Methacetin Breath Test  may als o have a prognostic value  in assessment of  adult Subjects  at 
risk for liver disease deterioration.  
5 STUDY DESIGN  
Please refer to protocol s MB130 -068 and MB130 -069.  
This study is a feasibility companion protocol that will use the data generated by BMS 's 
study of BMS -986036  under protocol s MB130 -068 and MB130 -069 (IND  125297 ), which 
are considered in this companion protocol as two separate study cohorts (1 and 2, 
respectively) . The MB130 -068 and MB130 -069 studies are Phase  2b, multicenter, double -
blind, randomized, placebo -controlled, parallel -group  studies to evaluate the safety and 
efficacy of BMS -986036  in improving  fibrosis without worsening of NASH , and long term 
clinical outcomes  in subjects with NASH and stage 3 liver  fibrosis  or compensated 
cirrhosis . The study is feasibility for drug response monitoring however the data may be 
used for Exalenz for future submissions.  
 
The study will consist of 4 periods:  
 A 4 to 8-week Screening Period  
 A 48 -week, Double -Blind Treatment Period, during which the subjects will receive 
blinded study medication ( BMS-9860936 10mg QW,  BMS -986036  20mg QW , BMS -
9860936 40mg QW or matching placebo QW  in a 1:1:1:1 ratio ). 
 Study visits every 4 weeks up to week 24 and every 8 weeks after week 24 up to 
week 48 , while MBT will only be performed every 24 weeks . 
 A Follow up Period, during which subjects will be evaluated for safety and efficacy 
for 4 weeks through week 52.  
Exalenz Bioscience Ltd.  Last update : February 20, 2018  
Study Title: Companion protocol for the ¹³C -Methacetin Breath 
Test (MBT)  for use in  Bristol -Myers Squibb phase  2b studies 
for BMS -986036  (PEG -FGF21) , under Protocols MB130 -068 
and MB130 -069 Protocol: BMS -EX-0118  
Version:  1.0 
Document No:  CSP000002  Page 18 of 38 
 
Exalenz Bioscience Ltd.    201 8  CONFIDENTIAL AND PROPRIETARY   A Follow -Up Period of at least 6 months and up to 14 months after the week 
52/PTFU Visit for collection of any liver related complication event.  
 
As part of the MB130 -068 and MB130 -069 studies, the MBT will be performed on Day1 
and every 24 weeks  during the Double -Blind Treatment Period,  to assess whether BMS -
986036 compared to placebo improves liver metabolic function as determined by the 
Methacetin Breath Test.  
6 SUBJECT SELECTION  
This feasibility companion protocol assesses the data for all subjects being enrolled  under 
MB130 -068 and  MB130 -069 protocols that consent to perform the MBT at sites 
perform ing MBT. Subjects will be screened according to the inclusion/exclusion criteria of 
the MB130 -068 and  MB130 -069 protocol s, and will be randomly assigned to a study 
treatment arm if they meet all the criteria.  Those Subjects  enrolled into those two separate  
BMS sponsored studies (MB130 -068, MB130 -069, respectively) and will be considered as 
two separate study cohorts (cohort 1 and 2, respectively) for this companion protocol.  
6.1 Inclusion Criteria  
This protocol follows the inclusion criteria as defined in the respective main protocols; 
MB130 -068 and MB130 -069 considered as two distinct study cohorts for this companion 
protocol . This feasibility companion protocol assesses the data for all subjects t hat perform 
the breath test under the MB130 -068 and MB130 -069 protocols, including their clinical 
follow up information.  
Cohort 1 includes study Subjects  with NASH and stage 3 fibrosis  that meet all the MB130 -
068 study criteria  that performed the MBT . 
Coho rt 2 includes study Subjects  with NASH and compensated  liver cirrhosis  that meet all 
the MB130 -069 study criteria  that performed the MBT . 
6.2 Exclusion Criteria  
Exclusion  criteria are as those in the  respective  BMS  protocol s; MB130 -068 and  MB130 -
069 considered as two distinct study cohorts for this companion protocol . Additionally, 
subjects designated to perform  the MBT that are known to be hypersensitive or allergic to 
Methacetin or its metabolites, e.g. acetaminophen (paracetamol) , may not perform t he 
MBT.  
Exalenz Bioscience Ltd.  Last update : February 20, 2018  
Study Title: Companion protocol for the ¹³C -Methacetin Breath 
Test (MBT)  for use in  Bristol -Myers Squibb phase  2b studies 
for BMS -986036  (PEG -FGF21) , under Protocols MB130 -068 
and MB130 -069 Protocol: BMS -EX-0118  
Version:  1.0 
Document No:  CSP000002  Page 19 of 38 
 
Exalenz Bioscience Ltd.    201 8  CONFIDENTIAL AND PROPRIETARY  6.3 Exclusion Criteria from MBT testing On the day of the test 
1. Subject should be fasting, including all oral morning medications (except for 
beta-blockers and study drug [ BMS -986036  or placebo]), for at least 8 hours 
prior to the test  
2. Subject should not smoke on the day of the breath test prior to the breath test  
3. Subject should not take any of the following drugs within 48 hours prior to 
the test: acyclovir, allopurinol, carbamazepine, cimetidine, ciprofloxacin, 
daidzein (herbal), disu lfiram, echinacea, enoxacin, famotidine, fluvoxamine, 
methoxsalen, mexiletine, montelukast, norfloxacin, phenylpropanolamine, 
phenytoin, propafenone, rifampin, terbinafine, ticlopidine, thiabendazole, 
verapamil, zileuton or any medication that might interf ere with methacetin 
metabolism or might affect CYP1A2 (cytochrome P450 1A2)  
4. Subject should not take amiodarone within 30 days prior to the test  
5. Subject should not take paracetamol (acetaminophen) related medications 
within the 24 hours prior to the test  
6. Subject should not perform the test if allergic or hypersensitive to Methacetin 
or its metabolites (paracetamol, acetaminophen)  
7. Subject should not consume any alcohol or caffeine within 24 hours prior to 
the test  
8. Subject should not have general anesthesia  or sedation within 24 hours prior 
to the test  
9. Subjects on beta -blockers or statins should be on a stable dose at least 30 
days prior to the test  
6.4 Consenting  
Prior to study participation Subjects ’ and/or their representative will be consented and sign  
two informed consent forms (ICFs):  One appropriate consent form as part of BMS' s 
MB130 -068 or MB130 -069 studies  and  another appropriate separate ICF as part of BMS' s 
MBT sub -study according to IRB preference . 
The consent will include willingness to share dat a with Exalenz and allow acquisition and 
collation of blood, clinical and imaging data taken on entry to the study, and incorporate all 
other data from the time of admission until the subject's termination from the study.  
Exalenz Bioscience Ltd.  Last update : February 20, 2018  
Study Title: Companion protocol for the ¹³C -Methacetin Breath 
Test (MBT)  for use in  Bristol -Myers Squibb phase  2b studies 
for BMS -986036  (PEG -FGF21) , under Protocols MB130 -068 
and MB130 -069 Protocol: BMS -EX-0118  
Version:  1.0 
Document No:  CSP000002  Page 20 of 38 
 
Exalenz Bioscience Ltd.    201 8  CONFIDENTIAL AND PROPRIETARY  7 STUDY OBJECTIVES  
The feasibility companion study aims  to evaluate the capabilities of the MBT  to assess the 
progression of NASH and monitor changes in NASH subjects  with significant fibrosis or 
compensated cirrhosis  with and without treatment.  
7.1 Primary Efficacy Objective  
To demonstrate  the ability of the MBT  to evaluat e patient response to treatment with 
BMS -986036  comparing placebo to each treatment arm  individually . Assessment will be 
performed at 24 and 48 weeks  and compared to  day 1  (change from baseline)  and the 
respective  preceding visit  (change between visits) , when available . Assessments will be 
done for each study cohort independently , according to availability and on the combined 
population of the two cohorts  by dose of the BMS drug under study . 
7.2 Secondary Efficacy Obje ctives  
The following assessments will be done by treatment arm and combined arms for each 
study cohort independently , according to availability , and on the combined population of 
the two study cohorts  by dose of the BMS drug under study :  
1. To demonstrate  the short and long -term prognostic value  (3 months , 6 months and 
1 year, respectively)  of MBT for liver disease deterioration  (reported as liver-
related clinical outcome events ). Assessment will be performed using MBT from 
the day 1, and 24 and  48 week visits . 
2. To assess  the ability of changes in the MBT to reflect  biopsy proven changes in 
fibrosis and/or NAS  as assessed by a central reader  at week  24 (or at least week 20  
in case s of an early termination time point) (for cohort 1) or at week 48 (for cohor t 
2) compared to the baseline biopsy from the screening visit.  
3. To assess  the ability of changes in the MBT to reflect  changes in liver stiffness as 
measured by Magnetic Resonance Elastography (MRE) where available  at weeks 
24 and 48 (or at early termination)  compared to baseline MRE from the screening 
visit. 
4. To assess  the ability of changes in the MBT to reflect  changes in Proton Density 
Fat Fraction (PDFF) as measured by Magnetic Resonance Imaging (MRI)  where 
available  - at weeks 24  and 48 (or early termination), compared to baseline  MRI 
from the screening visit . 
5. To assess the ability of changes in the MBT to reflect  changes in  Serum Pro -C3 at 
24 and 48 weeks of treatment (or early termination), compared to baseline Pro -C3 
from  the screening visit.  
 
Exalenz Bioscience Ltd.  Last update : February 20, 2018  
Study Title: Companion protocol for the ¹³C -Methacetin Breath 
Test (MBT)  for use in  Bristol -Myers Squibb phase  2b studies 
for BMS -986036  (PEG -FGF21) , under Protocols MB130 -068 
and MB130 -069 Protocol: BMS -EX-0118  
Version:  1.0 
Document No:  CSP000002  Page 21 of 38 
 
Exalenz Bioscience Ltd.    201 8  CONFIDENTIAL AND PROPRIETARY  The following additional objectives are applicable for cohort 2 only:  
1. To assess  the ability of changes in the MBT to reflect  changes in liver stiffness as 
measured by  "Fibroscan " elastography  at the 48 week visit (or earlier if there was  
an early termination)  compared to the screening visit.  
2. To assess  the ability of changes in the MBT to reflect  changes in the Model for 
End-stage Liver Disease (MELD) score at 24 and  48 week  visits compared to study 
day 1.  
3. To assess  the ability of changes  in the MBT to reflect  changes in the Child -
Turcotte -Pugh Scoring (CTP) score  at weeks  24 and  48 (or earlier if there was an 
early termination)  compared to study day 1.  
7.3 Exploratory Efficacy Objectives  
To assess the ability of the  MBT  to monitor patient status  in comparison to other available 
measures, such as Liver Fibrosis stage as assessed by  NAS, MELD , CTP, PDFF,  Liver 
Stiffness , Serum Biomarker or Pro-C3.  
7.4 MBT  Safety Objective  
All adverse events, serious adverse events (SAE s), suspected unexpected serious adverse 
reactions (SUSAR)  and unanticipated adverse device effect s (UADE)  will be reported 
according to local regulations. The actual reporting is discussed in section 11. No breath -
test related serious adverse events are expected.  For more information please refer to the 
Investigator 's Brochure.   
7.5 Primary Efficacy Endpoint  
MBT measure ment s throughout this  feasibility  companion study and all clinical measures 
and outcomes as assessed under protocols MB130 -068 and MB130 -069 will be collected 
in order to assess the MBT's ability to measure the effect of BMS -986036 treatment on the 
metabolic capacity of the liver at 24 week  interval s during the Double -Blind Treatment 
Period , up to 48-weeks, as compared to changes in placebo treated subjects.  
Assessments will be done for each study cohort independently and according to 
availability , on the combined population of the two study cohorts  by dose of the BMS 
drug under study . 
7.6 Secondary Efficacy Endpoint  measure s 
In order to assess the correlation of MBT with other measures of liver disease  the following 
endpoint measures will be collected:  
Exalenz Bioscience Ltd.  Last update : February 20, 2018  
Study Title: Companion protocol for the ¹³C -Methacetin Breath 
Test (MBT)  for use in  Bristol -Myers Squibb phase  2b studies 
for BMS -986036  (PEG -FGF21) , under Protocols MB130 -068 
and MB130 -069 Protocol: BMS -EX-0118  
Version:  1.0 
Document No:  CSP000002  Page 22 of 38 
 
Exalenz Bioscience Ltd.    201 8  CONFIDENTIAL AND PROPRIETARY  For all study cohorts: MBT  results for each MBT visit ( day 1 , week 24, week 48, ) as well 
as changes in MBT results (CPDR30/PDR peak or other breath test parameters).   
 
The other measures of liver disease that will be collected in this study are as follows:  
 
Liver Fibrosis stage and  NAS  as determined by Liver Biopsy , PDFF as determined by MRI  
where available , Liver Stiffness as determined by MRE where available , Serum Biomarker 
Pro-C3  
 
Additional measures for cohort 2: MELD  and CTP scores , Liver Stiffness as determined by 
Fibroscan® Elastography, Liver -related  Clinical Outcome  defined as the first occurrence of 
any one of the following: all -cause mortality, MELD score ≥15, liver transplant, 
hepatocellular carcinoma (HCC), ascites requiring medical intervention, hospitalization (≥ 
24 hours) for onset of variceal bleed, hepatic encephalopathy, spontaneous bacterial 
peritonitis.  
7.7 Efficacy Variables  
Study procedures and timing are summarized in the Schedule of E vents of protocols 
MB130 -068 and MB130 -069. 
The following procedures or tools will be used to assess subjects’ disease activity during 
the study:  
 MBT at selected sites in subjects who opt in at Day 1, week 24 and week 48.  
 Liver biopsy at Screening (if no biopsy is available from within 6 months of the 
Screening Visit), week 24 (for subjects in protocol MB130 -068/cohort 1 ) or week 48 
(for subjects in protocol MB130 -069/cohort 2 ) 
o Histological assessments of fibrosis stage and  NASH activity (NAS)  
 Liver stiffness as determined by MRE at selected sites at  screening,  week 24 and week 
48 
 Hepatic fat fraction as determined by MRI at selected sites at screening,  week  24 and 
week 48.  
 Serum Biomarker  Pro-C3 at Screening, Day 1, week 24, week 48 and week 52. 
Additional variables for cohort 2:  
 Fibroscan® elastography at Screening and week 48 or early termination  
 MELD Scores at Screening, Day 1, every 4 weeks up to week 24, every 8 weeks up to 
week 48 and week 52.  
Exalenz Bioscience Ltd.  Last update : February 20, 2018  
Study Title: Companion protocol for the ¹³C -Methacetin Breath 
Test (MBT)  for use in  Bristol -Myers Squibb phase  2b studies 
for BMS -986036  (PEG -FGF21) , under Protocols MB130 -068 
and MB130 -069 Protocol: BMS -EX-0118  
Version:  1.0 
Document No:  CSP000002  Page 23 of 38 
 
Exalenz Bioscience Ltd.    201 8  CONFIDENTIAL AND PROPRIETARY   Child -Pugh scores at Screening, Day 1, every 4 weeks up to week 24 and every 8 weeks 
up to week 48 and week 52.  
 Liver -related  Clinical outcome events at each visit from Day 1 through week 52 and 
during the Long -Term Bone Mineral Density and Immunogenicity  Follow -Up Period  
(up to 14 Months after week 52 ).  
7.7.1 Liver Biopsy  
Liver biopsy will be conducted at Screening if no liver biopsy is available within 6 months 
prior to Screening. Liver biopsy will also be performed  at week 24 (for cohort 1 ) or week 
48 (for cohort 2 ). 
All histological assessments will be performed by a blinded central reader. The central 
reader will be a medical doctor, board certified in pathology, with experience in liver 
pathology in a clinical study setting. Details on the acquisition, qua lity requirements, 
histological preparation, and shipping of histological samples are in the respective Study 
Reference Manual.  
7.7.1.1  Histological Assessments  
The NASH Clinical Research Network (CRN) system will be used to score the histologic 
samples. The NASH CRN system is based on the concept that necro -inflammatory lesions 
and stage of fibrosis should be evaluated separately; it assesses liver biopsies for degree of 
steatosis (0 -3), lobular inflammation (0 -3), hepatocellular ballooning (0 -2), and fibrosis (0 -
4). The first 3 components are added together in an unweighted fashion to determine the 
NASH activity score (NAS) that ranges from 0 to 8. Fibrosis is staged separately on a 0 -4 
scale: 0 (none); 1 (perisinusoidal or periportal); 2 (perisinusoidal and porta l/periportal); 3 
(bridging fibrosis); 4 (cirrhosis). It should be noted , the NAS should not be considered a 
replacement for a p athologist’s diagnosis of NASH.  
Table 1 NAS Scoring System  
Histology Variable  Grade  Score  
Steatosis Grade  < 5%  0 
5-33% 1 
> 33-66% 2 
>66%  3 
Lobular Inflammationa none  0 
Exalenz Bioscience Ltd.  Last update : February 20, 2018  
Study Title: Companion protocol for the ¹³C -Methacetin Breath 
Test (MBT)  for use in  Bristol -Myers Squibb phase  2b studies 
for BMS -986036  (PEG -FGF21) , under Protocols MB130 -068 
and MB130 -069 Protocol: BMS -EX-0118  
Version:  1.0 
Document No:  CSP000002  Page 24 of 38 
 
Exalenz Bioscience Ltd.    201 8  CONFIDENTIAL AND PROPRIETARY  Histology Variable  Grade  Score  
< 2 1 
2-4 2 
> 4 3 
Ballooning  none  0 
few 1 
many  2 
a foci per x200 field  
Liver biopsy samples will be used by the site to assess NASH and fibrosis stage  as per the 
site's standard practice . 
7.7.2 Clinical Outcome Events  
Cohort 2  will be evaluated for the following liver-related clinical outcome events at every 
visit during the treatment periods:  
o All-cause mortality  
o MELD score ≥15 (with at least a 2 -point increase from Baseline)  
o Liver transplant  
o Ascites requiring medical intervention  
o Hospitalization (≥24  hours) for onset of variceal bleed  
o Hospitalization (≥ 24 hours) for hepatic encephalopathy  
o Hospitalization (≥ 24 hours) for spontaneous bacterial peritonit is 
o HCC  
7.7.3 Magnetic Resonance Elastography  (MRE)  
Magnetic Resonance Elastography (MRE ) is a non-invasive  medical imaging technique 
that measures the stiffness of soft tissues by introducing  shear waves  and imaging their 
propagation using  MRI. In NASH Subjects , MRE is reproducible, and it has a higher inter -
observer agreement for staging fibrosis compared to histopathology. Additionally, an 
improvement in MRE has been associated with an improvement in liver fibrosis, as 
observed on liver biopsy.  
While the abil ity to perform MRE is expanding, appropriate hardware and software is not 
available at every institution and therefore, MRE use is still limited. In this study, MRE 
will only be conducted at selected sites with MRE  capability . Images will be collected by 
Exalenz Bioscience Ltd.  Last update : February 20, 2018  
Study Title: Companion protocol for the ¹³C -Methacetin Breath 
Test (MBT)  for use in  Bristol -Myers Squibb phase  2b studies 
for BMS -986036  (PEG -FGF21) , under Protocols MB130 -068 
and MB130 -069 Protocol: BMS -EX-0118  
Version:  1.0 
Document No:  CSP000002  Page 25 of 38 
 
Exalenz Bioscience Ltd.    201 8  CONFIDENTIAL AND PROPRIETARY  the site and submitted to a central imaging vendor for evaluation. Sites will be trained 
before collecting images.  
Adequacy of MRE should be confirmed by the central imaging vendor prior to 
randomization and throughout the study and repeat imaging may be re quired due to QC 
failure.  
Detailed instructions on the conduct of the MRE, and the acquisition and submission of 
MRE data to the central reader will be provided in the study specific Imaging Manual.  
Any incidental findings of potential clinical relevance t hat are not directly associated with 
the objectives of the study should be evaluated and handled by the investigator per the 
site’s standard of care and clinical judgment.  
MRE will be performed at selected sites at Screening,  week 24 and week 48 or early 
termination.  
For subjects discontinuing study treatment, MRE will only be conducted if the date of 
discontinuation is more than 8 weeks from the date of the previous MRE.  
7.7.4 Fibroscan® Elastography  
Fibroscan® is a non -invasive device that assesses the ‘hardness’ (or stiffness) of the liver 
via the technique of transient elastography. This procedure will only be performed for 
study cohort 2. Liver hardness is evaluated by measuring the velocity of a vibration w ave 
(also called a ‘shear wave’) generated on the skin. Shear wave velocity is determined by 
measuring the time the vibration wave takes to travel to a particular depth inside the liver. 
Because fibrous tissue is harder than normal liver, the degree of hep atic fibrosis can be 
inferred from the liver hardness.  
With the subject lying supine, an ultrasound -like probe is placed on the skin over the liver 
area, typically in the right mid -axillary line. The subject will feel a gentle ‘flick’ each time 
a vibration  wave is generated by the probe.  
A minimum of 10 valid readings, with at least a 60% success rate and an interquartile range 
of ≤ 30% of the median value, are taken with the results expressed in kilopascals (kPa).  
7.7.5 Magnetic Resonance Imaging  (MRI)  
At selected sites, proton density hepatic fat fraction Hepatic Magnetic Resonance Imaging 
(MRI ) will be employed to determine hepatic fat fraction.  This is a non -invasive and 
accurate MRI -based biomarker utilized for liver fat quantification  by measuring t he 
proportion of mobile proton density of the liver . In NASH Subjects , MRI -Proton Density Fat 
Fraction  accurately classifies grades and changes in hepatic steatosis, and a  ≥ 29% 
Exalenz Bioscience Ltd.  Last update : February 20, 2018  
Study Title: Companion protocol for the ¹³C -Methacetin Breath 
Test (MBT)  for use in  Bristol -Myers Squibb phase  2b studies 
for BMS -986036  (PEG -FGF21) , under Protocols MB130 -068 
and MB130 -069 Protocol: BMS -EX-0118  
Version:  1.0 
Document No:  CSP000002  Page 26 of 38 
 
Exalenz Bioscience Ltd.    201 8  CONFIDENTIAL AND PROPRIETARY  reduction in MRI -Proton Density Fat Fraction has been associated with histolog ical NAS 
improvement.  
Images will be collected by the site and submitted to a central imaging vendor for 
evaluation. Sites will be trained before collecting images.  
Adequacy of MRI will be confirmed by the central imaging vendor prior to randomization 
and throughout the study and repeat may be required due to QC failure.  
Detailed instructions on the conduct of the MRI, and the acquisition and submission of 
MRI data to the central reader will be provided in the study specific Imaging Manual.  
Any incidental findings of potential clinical relevance that are not directly associated with 
the objectives of the study are intended to  be evaluated and handled by the investigator per 
the site’s standard of care and clinical judgment.  
Hepatic fat fracti on is determined by MRI -based proton density fat fraction (PDFF) at 
Screening, week 24, and week  48/ET  
For subjects discontinuing study treatment, MRI should only be conducted if the date of 
discontinuation is more than 8 weeks from the date of the previou s MRI  
7.7.6 Serum Biomarker Pro -C3 
Blood samples will be collected at each visit for the assessment of exploratory biomarkers. 
Exploratory biomarkers in serum, plasma, and whole blood, will be used to assess markers 
of fibrosis and associated diseases and pathwa ys (including cardiovascular disease, 
inflammation, diabetes, kidney disease as well as liver disease, and possibly bone). These 
studies include  amongst others , Serum Pro -C3, AN N-terminal propeptide of type 3 
procollagen (P3NP) and specific fragment of MM P-9-mediated degradation of type III 
collagen (C3M)  
Pro-C3 levels in Subjects  will be measured at week 4, week 8, week 12, week 24, week 48, 
and week  52 (post treatment follow up)  
7.7.7 MELD Scoring  
MELD scoring , to be performed for cohort 2  (see Appendix 10  of study protocol  MB130 -
069) is a score  for assessing the severity of chronic liver disease that does not include 
subjective variables such as ascites and encephalopathy. It employs the subject’s bilirubin, 
serum creatinine, and  prothrombin time (INR).  
Blood  samples will be taken for bilirubin, serum creatinine, and prothrombin time as part 
of the hematology and serum chemistry assessments conducted at each visit. The same 
central laboratory will be used for each evaluation. The central laboratory will calcul ate the 
Exalenz Bioscience Ltd.  Last update : February 20, 2018  
Study Title: Companion protocol for the ¹³C -Methacetin Breath 
Test (MBT)  for use in  Bristol -Myers Squibb phase  2b studies 
for BMS -986036  (PEG -FGF21) , under Protocols MB130 -068 
and MB130 -069 Protocol: BMS -EX-0118  
Version:  1.0 
Document No:  CSP000002  Page 27 of 38 
 
Exalenz Bioscience Ltd.    201 8  CONFIDENTIAL AND PROPRIETARY  MELD score based on the laboratory values and communicate the score to the site. MELD 
scores will be determined at each study visit. 
7.7.8 Child -Turcotte -Pugh (CTP) Scoring  
The Child -Turcotte -Pugh (CTP) score assesses the severity of cirrhosis  and will be done 
for cohort 2 Subjects . It has been shown to be an accurate measure across a broad spectrum 
of liver disease. It employs numerical scores of 5 measures of liver disease: total bilirubin, 
serum albumin, international normalized ratio for INR, ascites, and encephalopathy and is 
score d according to the scheme in Appendix 8 of study  protocols  MB130 -068 and  MB130 -
069. The sum of scores from each component is the final score.  
Blood samples will be collected for the total bilirubin, serum albumin, and prothrombin 
time assessments used to c alculate the CTP score as part of the hematology and serum 
chemistry assessments conducted at each visit. The same central laboratory will be used for 
each evaluation. Evaluations of ascites and encephalopathy are to  be conducted by the 
same site personnel  at each visit wherever possible.  
CTP scores will be determined at each study visit . 
7.7.9 13C-Methacetin Breath Test (MBT)  
The 13C-Methacetin Breath Test ( MBT ) is a non -invasive tool that provides an estimate of 
liver function by assessing microsomal capacity t o metabolize the non -radioactive 13C-
labeled Methacetin. MBT measures carbon dioxide exhaled into a nasal cannula before and 
after drinking a non -radioactive solution (called ¹³C-methacetin), using a device called the 
BreathID® MCS device. The amount of 13carbon dioxide (13CO 2) exhaled over 60 -85 
minutes will then be measured. The MBT, which consists of both a device and an 
unapproved drug component, is considered an investigational device that has not been 
reviewed, approved or cleared by the FDA for marke ting purposes.  
In Subjects  evaluated/listed for liver transplantation, a reduction in exhaled 13CO 2 has been 
associated with an increased risk of cirrhotic complications (3). MBT will be conducted at 
selected sites in subjects who provide consent . The test will be performed after an 8 -hour 
fast according to study guidelines and as per the manufacturer ’s instructions.  
MBT will be conducted at  Day 1 visit prior to first dose of treatment, week 24 and week 
48. For participants discontinuing study treatment at sites selected for the MBT sub-study , 
MBT should be conducted only if the date of discontinuation is more than 12 weeks from 
the date of the previous MBT.  
Exalenz Bioscience Ltd.  Last update : February 20, 2018  
Study Title: Companion protocol for the ¹³C -Methacetin Breath 
Test (MBT)  for use in  Bristol -Myers Squibb phase  2b studies 
for BMS -986036  (PEG -FGF21) , under Protocols MB130 -068 
and MB130 -069 Protocol: BMS -EX-0118  
Version:  1.0 
Document No:  CSP000002  Page 28 of 38 
 
Exalenz Bioscience Ltd.    201 8  CONFIDENTIAL AND PROPRIETARY  8 SAFETY TERMINATION A ND EARLY WITHDRAWAL OF 
SUBJECT S OR STUDY  
For safety termination and early withdrawal of subjects please refer to BMS ’s protocol s 
MB130 -068 and MB130 -069. 
8.1 Expected Study Duration  
BMS ’s protocol s MB130 -068 and MB130 -069 plan to have subjects remain on study for a 
total of at least 52 weeks  including the Double -Blind Treatment Period  and the post -
treatment follow -up visit (PTFU) , unless intolerable side effects develop or the subject is 
withdrawn from study participation. Subjects will have up to a n 8-week screening period , a 
4 week post -treatment  follow -up visit  and a  Follow -Up Period of at least 6 months and up 
to 14 months after the week 52/PTFU .  
For participants discontinuing study treatment at sites selected for the MBT sub-study, 
MBT should be conducted only if the date o f discontinuation is more than 12 weeks from 
the date of the previous MBT.  
9 STATISTICAL CONSIDER ATIONS  
9.1 Study Design and Aim 
This study is design ed as a feasibility companion protocol that will use the data generated 
by BMS ’ studies of BMS -986036 under protocol s MB130 -068 and MB130 -069 for which 
one of the exploratory objectives is to assess whether BMS -986036  compared to placebo 
improves liver metabolic function as assessed by  the 13C-Methacetin Breath Test .  
Additional analyses may be performed by Exalenz on the data to be received from these 
BMS  studies. The study is feasibility for drug response monitoring however the data may 
be used for Exalenz for future submissions.  
9.2 Endpoint Measures  
9.2.1 Primary endpoint measure  
In order to show the ability of the MBT to measure the effect of BMS -986036 
treatment on the metabolic capacity of the liver after 24 weeks, 48 -weeks, as compared 
to changes in placebo treated subjects the primary endpoint will be analyzed using a 
Mixed Effect Repeated Measures (MMRM) Model.  An unstructured correlation matrix 
will be used to model within -patient errors and restricted maximum likelihood 
estimation will be used. The Kenwood -Roger method will be used for the denominator 
Exalenz Bioscience Ltd.  Last update : February 20, 2018  
Study Title: Companion protocol for the ¹³C -Methacetin Breath 
Test (MBT)  for use in  Bristol -Myers Squibb phase  2b studies 
for BMS -986036  (PEG -FGF21) , under Protocols MB130 -068 
and MB130 -069 Protocol: BMS -EX-0118  
Version:  1.0 
Document No:  CSP000002  Page 29 of 38 
 
Exalenz Bioscience Ltd.    201 8  CONFIDENTIAL AND PROPRIETARY  degrees of free dom. Should the model fail to converge with an unstructured covariance 
matrix, Toeplitz and Compound -Symmetric structures will be applied.  
The MMRM model will include change from baseline as outcome, and Study Arm, 
Visit, Study Arm*Visit Interaction, Basel ine value and site as covariates.  
Assessments will be done for each study cohort independently and according to 
availability and on the combined population of the two study cohorts  by dose of the 
BMS drug under study .  
A sensitivity analysis of the primary  endpoint will be performed excluding subjects 
with significant protocol violations. Additional sensitivity analyses will be performed if 
deemed necessary. Such analyses as well as additional details will be described in the 
SAP.  
9.2.2 Secondary endpoint measure s 
The following assessments will be done by treatment arm and combined arms for each 
study cohort independently , according to availability and on the combined population of 
the two  study cohorts  by dose of the BMS drug under study : 
1. In order to assess the prognostic value of MBT in prediction of liver disease 
deterioration  (reported as liver-related clinical outcome events ), the endpoint 
measures will be point estimates of Cox Regression's  Hazard Ratio or Logistic 
Regression's Relative Risk  (as appropriate)  at least at 48 weeks for classifying 
Subjects  into risk groups for clinical deterioration  with respective exact two -sided 
95% confidence intervals in the placebo and treatment arms as determined by MBT.  
2. Repeat MBT results (CPDR30/PDR peak or other breath test parameters)  and their 
change s in subjects with and without treatment ( BMS -986036 ) for nonalcoholic 
steatohepatitis (NASH) at Day 1 , week 24 and 48 (or early termination) will be 
compared and tested for correlation to baseline as well as repeat results  for the 
following measurements:  
a. Biopsy based Fibrosis  and/or NAS score  
b. Liver stiffness as measured by  MRE  
c. PDFF  as measured by MRI   
d. Serum Pro -C3 results  
e. Liver elastography by Fibroscan  (in cohort 2 only)  
f. MELD scores  (in cohort 2 only)  
Exalenz Bioscience Ltd.  Last update : February 20, 2018  
Study Title: Companion protocol for the ¹³C -Methacetin Breath 
Test (MBT)  for use in  Bristol -Myers Squibb phase  2b studies 
for BMS -986036  (PEG -FGF21) , under Protocols MB130 -068 
and MB130 -069 Protocol: BMS -EX-0118  
Version:  1.0 
Document No:  CSP000002  Page 30 of 38 
 
Exalenz Bioscience Ltd.    201 8  CONFIDENTIAL AND PROPRIETARY  CTP scores  (in cohort  2 only)  Linear Regr ession will be applied in order to test for 
significance of the correlations between MBT and the liver measurements listed 
above.  
Changes in MBT are measured as the difference between baseline and each of the  
MBT visit s as well as the c hange in measurements between two subsequent visits in 
each of the two treatment groups.  
The metabolic capacity of the liver as determined by the MBT cumulative 
percentage dose recovery at 30 minutes (CPDR30)  will be the main MBT parameter 
of interest . 
Nevertheless,  available breath test parameters (Delta  Over Baseline - DOB at the 
respective times) will be collected from the completed eCRFs. The DOBs will be 
transformed to percentage dose recovery – PDR, by normalizing the DOB using 
patient weight and heig ht. The Area under the DOB and under the PDR curve will 
be calculated at 5 -minute time intervals resulting in cDOB and cPDR at 5, 10, 15, 
20, 25, 30, 35, 40, 45, 50, 55 and 60 minutes respectively. Analys es may be done 
using any of the  MBT derived paramete rs. 
9.2.3 Safety endpoints measure  
The cumulative incidence of adverse events, serious adverse events (SAE), suspected 
unexpected serious adverse reactions (SUSAR) and unanticipated adverse device effect s 
(UADE) possibly or probably related to the use of the BreathID MCS device and its 
substrate or related to the procedure , will be collected and reported.  
9.3 Acceptance Criteria (Study Hypotheses)  
At least one cut -off in changes of MBT values will be determine d to show that MBT is a 
potential measure that can assess the response to treatment for BMS -986036 . 
At least one cut -off, to be determined by the algorithm being developed by Exalenz using 
data from IDE# G080227, will be validated in this study to classify  Subjects  into risk 
groups for deterioration of liver function related events.  
9.4 Sample Size  
Subjects  that are enrolled into two separate BMS sponsored IND studies (MB130 -068, 
MB130 -069, respectively)  at selected study sites  will be offered the opportunity  to perform 
the MBT and will be considered as two separate study cohorts (cohort 1 and 2, 
respectively) for this companion protocol. Each cohort consists of four treatment arms 
(BMS -986036 10mg, 20mg , 40mg  QW or matching placebo QW)  as defined in the 
respective BMS sponsored protocols.  
Exalenz Bioscience Ltd.  Last update : February 20, 2018  
Study Title: Companion protocol for the ¹³C -Methacetin Breath 
Test (MBT)  for use in  Bristol -Myers Squibb phase  2b studies 
for BMS -986036  (PEG -FGF21) , under Protocols MB130 -068 
and MB130 -069 Protocol: BMS -EX-0118  
Version:  1.0 
Document No:  CSP000002  Page 31 of 38 
 
Exalenz Bioscience Ltd.    201 8  CONFIDENTIAL AND PROPRIETARY   
Cohort 1 consists of Subjects  with NASH and stage 3 fibrosis , as assessed by a central 
laboratory reader of the liver biopsies (n=160) , and who  meet all the MB130 -068 study 
criteria.  
 
Cohort 2  consists of Subjects  with NASH and compensated  liver cirrhosis  (stage 4 fibrosis) 
as assessed by a central laboratory reader of the liver biops ies (n=100) , and who  meet all 
the MB130 -069 study criteria.  
 
This feasibility companion protocol will include those 2 cohorts of subj ects, which are 
planned for  up to 260 subjects ) from  approximately 75 sites worldwide (USA and Japan)  
for the two BMS IND studies, while the MBT will only be conducted in the USA . 
Not all participating sites will elect  to perform the MBT. The total number of subjects 
expected to perform the MBT may reach up to 250 subjects  (also accounting for drop outs) . 
Each subject  will perform up to 3 MBTs over 1 year . 
9.5 Analysis sets  
Safety Analysis Set:  
All subjects enrolled under  BMS' MB130 -068 and MB130 -069 studies who have 
performed the MBT test at least one time.  
Efficacy Analysis Set:  
All subjects enrolled under  BMS' MB130 -068 and MB130 -069 studies who have 
successfully performed the MBT test and did not have any major protocol deviations for 
the current study.  
Safety analyses will be performed on the safety analysis set and efficacy analyses on the 
efficacy analysis set.  
9.6 Statistical Analysis  
9.6.1 General Considerations  
Statistical analyses will be performed using R software  version 3.4. 3 or higher  (R 
Development Core Team. Vienna, Austria).  
If any statistical tests are performed, they will be two -sided. The required significance level 
of findings will be equal to or lower than 5%. Where confidence limits (CL) are 
appropriate, the confidence level w ill be 95%.  
Exalenz Bioscience Ltd.  Last update : February 20, 2018  
Study Title: Companion protocol for the ¹³C -Methacetin Breath 
Test (MBT)  for use in  Bristol -Myers Squibb phase  2b studies 
for BMS -986036  (PEG -FGF21) , under Protocols MB130 -068 
and MB130 -069 Protocol: BMS -EX-0118  
Version:  1.0 
Document No:  CSP000002  Page 32 of 38 
 
Exalenz Bioscience Ltd.    201 8  CONFIDENTIAL AND PROPRIETARY  Baseline values are defined as the last valid value prior to investigational treatment start.  
Study data will be summarized by descriptive statistics. Continuous variables will be 
summarized by a mean, standard deviation, minimum, median and ma ximum, and 
categorical variables by a count  frequency  and percentage. Confidence intervals will be 
provided where relevant.  
9.6.2 Demographic and other Baseline Characteristics  
Demographic, medical and clinical history variables will be tabulated. Continuous 
variables will be summarized by a mean, standard deviation, minimum, median and 
maximum, and categorical variables by a count  frequency  and percentage.  
9.6.3 Disposition of Subjects  
The numbers of subject s who were enrolled will be provided, as well as the reasons for all 
enrollment discontinuations, grouped by major reason (e.g., lost to follow -up, adverse 
event, poor compliance). A list of discontinued subject s, protocol deviations, and subject s 
excluded from the efficacy analysis will be provided as well.  
9.6.4 Safety Analysis  
The adverse events possibly or probably related to Methacetin and/or the BreathID® MCS 
device will be presented along with a two sided 95% exact binomial confidence interval. 
The analysis of all adverse events will include incidence tables and wil l include analyses by 
severity, relationship to device or drug and baseline variables.  
9.6.5 Interim Analysis  
As part of BMS's MB130 -068 protocol, a n unblinded interim analysis of efficacy data will 
be conducted by a team separate from the blinded study team conducting and monitoring 
the study for the purpose of re -assessment of the response rate assumptions for the primary 
endpoint for BMS -986036 and placebo and re -estimate the sample size to provide adequate 
power if necessary. This interim analysis will be performed at a time to maximize the 
information available for the primary endpoint but without necessitating a pause in the 
recruitment for the study. Based on enrollment projections and given the 48 -week follow -
up prior to liver biopsy, this interim analy sis is expected to occur when post -treatment liver 
biopsy measurements are available for at least the first 100 randomized subjects  from 
cohort 1 . The sample size re -estimation will be based only on the primary histological 
endpoint from the liver biopsy, proportion of subjects with ≥ 1 -stage improvement in 
fibrosis without worsening of NASH. The primary histology endpoint will be compared 
between BMS -986036 and placebo using a Wald statistic at a one -sided level of 
Exalenz Bioscience Ltd.  Last update : February 20, 2018  
Study Title: Companion protocol for the ¹³C -Methacetin Breath 
Test (MBT)  for use in  Bristol -Myers Squibb phase  2b studies 
for BMS -986036  (PEG -FGF21) , under Protocols MB130 -068 
and MB130 -069 Protocol: BMS -EX-0118  
Version:  1.0 
Document No:  CSP000002  Page 33 of 38 
 
Exalenz Bioscience Ltd.    201 8  CONFIDENTIAL AND PROPRIETARY  significance of 0.005. It is also expecte d that the final sample size will be no more than 
50% higher than the original planned sample size.  
9.6.6 Pooling  
As there will be very few subjects  enrolled  at any given site , data from all sites will be 
pooled for analyses  for each study cohort separately and combined cohorts .  
9.6.7 Handling of Missing Data  
The study variables cannot be evaluated for subject s for whom BreathID® MCS device 
MBT  results  are not available and therefore these subjects will be left out of the efficacy 
analysis . Subjects missing clinical outcome  and biopsy  result s will be excluded from the 
analyses .  
10 STUDY PROCEDURES  
10.1  General  
The schedule of th e breath tests is based on the schedule of the MB130 -068 and MB130 -
069 protocol s. The first MBT will be performed on Day 1 . The subsequent  MBT s will be 
performed at 24  -week interval  visits in the Double -Blind Treatment Period . 
10.2  Breath Test Procedure  
Preparation of the study subject  
Once consented , the Subjects  will perform the breath test  on day 1  prior to first dose 
treatment , at 24 and 48 week s of treatment  prior to dose  uptake  and biopsy  procedure  if 
relevant . In preparation for each breath test the patient will be asked to comply w ith the 
following precautions : 
1. Subject should be fasting, including all oral morning medications (except for beta-
blockers and study drug [ BMS -986036  or placebo]), for at least 8 hours prior to the 
test  
2. Subject should not smoke on the day of the breath test prior to the breath test  
3. Subject should not take any of the following drugs within 48 hours prior to the test: 
acyclovir, allopurinol, carbamazepine, cimetidine, ciprofloxacin, daidzein (herbal), 
disulfiram, echinacea, enoxacin, famotidine, fluvoxamine, methoxsalen, mexiletine, 
montelukast, norfloxacin, phenylpropanolamine, phenytoin, propafenone, rifampin, 
terbinafine, ticlopidine, thiabendazole, verapamil, zileuton or any medication that 
might interfere with methacetin metabolism or might affect CYP1A2 (cytochrome 
P450 1A2)  
4. Subject should not take amiodarone within 30 days prior to the test  
Exalenz Bioscience Ltd.  Last update : February 20, 2018  
Study Title: Companion protocol for the ¹³C -Methacetin Breath 
Test (MBT)  for use in  Bristol -Myers Squibb phase  2b studies 
for BMS -986036  (PEG -FGF21) , under Protocols MB130 -068 
and MB130 -069 Protocol: BMS -EX-0118  
Version:  1.0 
Document No:  CSP000002  Page 34 of 38 
 
Exalenz Bioscience Ltd.    201 8  CONFIDENTIAL AND PROPRIETARY  5. Subject should n ot take paracetamol (acetaminophen) related medications within 
the 24 hours prior to the test  
6. Subject should not perform the test if allergic or hypersensitive to Methacetin or its 
metabolites (paracetamol, acetaminophen)  
7. Subject should not consume any alcohol or caffeine within 24 hours prior to the test  
8. Subject should not have general anesthesia or sedation within 24 hours prior to the 
test 
9. Subjects on beta -blockers or statins should be on a stable dose at least 30 days prior 
to the test  
Preparation of 13C-Methacetin  
Exalenz Bioscience Ltd. will provide 75 mg 13C-Methacetin doses in a 0.05% solution of 
¹³C-Methacetin in purified water, supplied, in amber thermoplastic polyester (PET) bottles 
with a child resistant plastic  cap. No preparation is needed other than pouring the contents 
of the solution into a cup for ingestion.  
Performance of the breath test  
Only trained personnel  will perform the breath test procedure. The actual breath collection 
is automatically performed b y the device and is not operator dependent. If the IDcircuit (a 
nasal cannula manufactured specifically for Exalenz) is not connected properly to the 
subject (e.g. the breath does not reach the device), the BreathID® MCS device will prompt 
the operator to adjust the IDcircuit.  
1. Turn on the device from the switch in the rear and allow up to 1 hour for warm -up 
to complete. To perform the test, ensure that the BreathID® MCS screen shows that 
the device is in ‘Ready’ state.  
2. The IDcircuit will be attached to the BreathID® MCS device and to the patient. 
Pressing the “Start” button on the device will begin the collection of the patient’s 
baseline exhaled breath. This will take approximately 5 -10 minutes.  
3. The 13C-Methacetin solution is poured into a disposable cup and administrated to 
the patient when prompted by the device. The solution should be administered by a 
medical practitioner registered on the delegation log or a research nurse if specific 
training for administration has been given. Immediately after ingestion, the operator  
will press the "Continue" button , which activates the actual measurement. CO 2 
production with 13C may be visible within a few minutes in cases with relatively 
functional livers.  
Exalenz Bioscience Ltd.  Last update : February 20, 2018  
Study Title: Companion protocol for the ¹³C -Methacetin Breath 
Test (MBT)  for use in  Bristol -Myers Squibb phase  2b studies 
for BMS -986036  (PEG -FGF21) , under Protocols MB130 -068 
and MB130 -069 Protocol: BMS -EX-0118  
Version:  1.0 
Document No:  CSP000002  Page 35 of 38 
 
Exalenz Bioscience Ltd.    201 8  CONFIDENTIAL AND PROPRIETARY  Note:  In rare cases , the administration of fluids may cause vomiting. If this happens , the 
test should be aborted and repeated on one of the subsequent  days. The expe rienced  
adverse event should be reported in the appropriate CRF section.  
4. The patient should re main in a seated position breathing in a normal manner for up 
to 85 minu tes, while data is collected.  
5. The BreathID® MCS device continuously measures and analyzes the patient’s 
exhaled breath in real time. As the 13C-Methacetin is metabolized, the value of the 
13CO 2/12CO 2 ratio in the exhaled breath will change and will be calculated in real 
time by the device.  
6. If at any time the device does not detect patient’s breath, or if there is any other 
deviation from the desired test requirements, the device will pr oduce an appropriate 
warning message on the screen.  
7. At the completion of the MBT , the device screen will indicate that the test is 
completed and a printout will be generated. T he IDcircuit is then removed and the 
patient is disconnected from the BreathID® MCS device.  
The patient will be under the supervision of the physician or any other qualified medical 
staff during the entire test.  
The operators will be trained how to terminate the breath test early. In the following 
situations, the MBT  will be terminated and a termination form will be completed:  
1. The patient vomits after ingestion of the substrate.  
2. The BreathID® MCS device malfunctions ( in this case, the operator will complete a 
technical complaint form in addition to the termination form and con tact Exalenz 
immediately for further instructions) af ter ingestion of the substrate.  
In all these cases,  MBT  cannot be repeated the same day for that specific subject  that has 
already ingested 13C-Methacetin . Efforts should be made to  repeat  the MBT  on one  of the 
subsequent  days. An entry will be made in the drug/kit accountability log and the 13C-
Methacetin bottles will be kept for inspection by the study monitor.  
10.3  Investigational Product Handling  
The Investigator and Research Pharmacist (if relevant) will  be provided with 
Investigational Product Handling Guidelines  that will provide details regarding the 
packaging and labeling requirements, receipt of investigational product, dispensing and 
accountability procedures, preparation instructions, storage and stability of the 
Investigational product  and disposi tion of the Investigational Product . 
Exalenz Bioscience Ltd.  Last update : February 20, 2018  
Study Title: Companion protocol for the ¹³C -Methacetin Breath 
Test (MBT)  for use in  Bristol -Myers Squibb phase  2b studies 
for BMS -986036  (PEG -FGF21) , under Protocols MB130 -068 
and MB130 -069 Protocol: BMS -EX-0118  
Version:  1.0 
Document No:  CSP000002  Page 36 of 38 
 
Exalenz Bioscience Ltd.    201 8  CONFIDENTIAL AND PROPRIETARY  10.4  Investigational Product Accountability  
The Investigator and Study Pharmacist (if relevant) are responsible for ensuring that all 
study supplies received at the site are inventoried and accounted for throughout the study. 
The disp ensing of study substrate to the subject must be documented in the respective 
accountability form. The study Investigational Product must be stored in a limited access 
area or in a locked cabinet under appropriate environmental conditions. Unused study 
materials must be available for verification by the sponsor’s site monitor during on -site 
monitoring. The destruction of unused study materials (both, expired or unexpired) will be 
documented on the return/disposition form. The Sponsor will authorize destruct ion of 
excess supplies on site according to local policy  or arrange collection of unused supplies . 
In the case of local destruction , before proceeding, the site must seek authorization from 
the Sponsor using the return/destruction form and this must also b e documented o n the 
Study Supply Return Form.  
Study substrate should be dispensed under the supervision of the investigator, a qualified 
member of the investigational staff, or by hospital clinical pharmacist.  
11 ETHICS & REGULATORY CONSIDERATIONS  
The protoco l will be conducted in the US and Japan by BMS as Phase 2b studies of BMS -
986036,  MB130 -068 and MB130 -069. As such, regulatory requirements that  are relevant 
for pharmaceutical investigations in US and Japan that will be applicable during the studies 
are to be conducted and overseen by BMS . 
BMS will obtain for the  main study  an IND ( IND-125297 ) and the applicable regulatory 
approvals for the MBT sub -study and the use  of clinical data from all regulatory 
authorities (if relevant) and ethics committees /IRBs . 
12 SAFETY CONSIDERATION S 
All adverse events  (AE) , serious adverse events (SAE) , suspected unexpected serious 
adverse reactions (SUSAR)  and unanticipated adverse device effect s (UADE)  possibly or 
probably related to the use of the MBT  product or related to t he MBT  procedure will be 
collected and reported according to local regulations.  
Safety assessments of the BMS study drug (BMS -986036 ) will be performed as described 
in BMS protocol s MB130 -068 and MB130 -069. 
Exalenz Bioscience Ltd.  Last update : February 20, 2018  
Study Title: Companion protocol for the ¹³C -Methacetin Breath 
Test (MBT)  for use in  Bristol -Myers Squibb phase  2b studies 
for BMS -986036  (PEG -FGF21) , under Protocols MB130 -068 
and MB130 -069 Protocol: BMS -EX-0118  
Version:  1.0 
Document No:  CSP000002  Page 37 of 38 
 
Exalenz Bioscience Ltd.    201 8  CONFIDENTIAL AND PROPRIETARY  13 SUBJECT  CONFIDENTIALITY  
The subject ’s name and personal data will remain confidential and will not be published in 
any way. All data will be coded and stored in locked offices or on password protected 
computers.  
14 MONITORING AND QUALI TY ASSURANCE  
This study is a companion protocol that will use the data generated by the  BMS  Phase 2b 
studies of BMS -986036,  under protocol s MB130 -068 and MB130 -069. BMS  will ensure 
compliance with GCP, local regulations and scientific integrity and will manage and 
oversee the study conduct.  
15 PUBLICATION POLICY A ND FINANCE  
It is intended that the results of the companion study will be reported and disseminated at 
international conferences and in peer -reviewed scientific journals. The policy regarding 
publications appears in the non -disclosure agreement signed by each study part icipant prior 
to signing of the contract.  
16 FINANCIAL ASPECTS  
The BreathID® MCS device and  test kit including a nasal cannula and  a solution containing 
13C-Methacetin  will be provided by Exalenz Bioscience.  BMS  will be responsible for the 
funding of regulatory approvals  in regards to  their main protocol s and administration as 
well as for the funding for study support of staff at local sites.  
17 STUDY TERMINATION  
This study is a companion protocol that will use the data generated by BMS  from  its Phase 
2b studies of BMS -986036  under protocol s MB130 -068 and MB130 -069. BMS  will be 
responsible for study termination procedures, when applicable.  
18 REFERENCES  
1. Younossi ZM, Stepanova M, Rafiq N, Makhlouf H, Younoszai Z, Agrawal R, 
Goodman Z. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol 
agreement and ability to predict liver -related mortality. Hepatology 2011;53:1874 -
1882.  
2. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated 
aminotransferase levels in the United States. Am J Gastroenterol 2003;98:960 -967. 
Exalenz Bioscience Ltd.  Last update : February 20, 2018  
Study Title: Companion protocol for the ¹³C -Methacetin Breath 
Test (MBT)  for use in  Bristol -Myers Squibb phase  2b studies 
for BMS -986036  (PEG -FGF21) , under Protocols MB130 -068 
and MB130 -069 Protocol: BMS -EX-0118  
Version:  1.0 
Document No:  CSP000002  Page 38 of 38 
 
Exalenz Bioscience Ltd.    201 8  CONFIDENTIAL AND PROPRIETARY  3. Stravitz RT, Reuben A, Mizrahi M, Lalazar G, Brown K, Gordon SC, Ilan Y, et al. Use 
of the methacetin breath test to classify the risk of cirrhotic complications and mortality 
in Subjects  evaluat ed/listed for liver transplantation. J Hepatol 2015;63:1345 -1351.  
 